Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 166 participants.

Also called NCT02286258

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose diagnostic
Phase
Phase 1/2
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02286258
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02286258. Non-randomized; no masking; primary purpose diagnostic. Start 2014-10 (actual); primary completion 2017-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
Acronym
MultiGFR
Condition
Renal Insufficiency, Chronic
Condition
Kidney Diseases
Intervention (Drug)
Calcium EDTA
Intervention (Drug)
Gd-DOTA
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Ministry of Health, France (class: other government)

Record details

Record id
cardio:ct-nct02286258
Content hash
f34c4ef400256e562d1f3eee247609dcb2d388d0024b810fe1461c42fd638a57